Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DB-020 · 1 trial · 1 indication
To investigate the safety and tolerability of DB-020 when given intratympanically to patients receiving cisplatin chemotherapy treatment
| Arm | Type | Description |
|---|---|---|
| DB-020 for Injection, 12%/placebo | ACTIVE_COMPARATOR | dosage |
| DB-020 for Injection, 25%/placebo | ACTIVE_COMPARATOR | dosage |
| Name | Type | Description |
|---|---|---|
| DB-020 | DRUG | Injectable sterile viscous solution of DB-020 and sodium hyaluronate in sterile water |
| Placebo | DRUG | Injectable sterile viscous solution of sodium hyaluronate in sodium chloride |
Inclusion Criteria: * Ability to communicate with medical team and staff, willingness to participate in the study, give written informed consent, comply with the study restrictions * Adults aged 18 years, inclusive, or older * Treatment for cancer with Intervenous cisplatin once every 21 or 28 days...
DB-020 is an investigational small molecule being developed to protect hearing in patients receiving cisplatin for cancer treatment. It is intended to address ototoxicity, which is hearing damage caused by cisplatin chemotherapy. The drug is currently in Phase 1 clinical development.
DB-020 is being developed by Regeneron Pharmaceuticals, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol REGN. The company is conducting clinical research to evaluate the safety and efficacy of DB-020 in protecting hearing in patients undergoing cisplatin-based cancer treatment.
DB-020 is in Phase 1 clinical development. A Phase 1 clinical trial has been completed to evaluate the safety and efficacy of DB-020 in protecting hearing in patients receiving cisplatin for cancer treatment. The drug is investigational and has not been approved by regulatory authorities.
DB-020 has been studied in one completed Phase 1 clinical trial, identified as NCT04262336. This trial evaluated the safety and efficacy of DB-020 to protect hearing in patients receiving cisplatin for cancer treatment. The study enrolled 22 participants and was conducted in the United States and Australia.
DB-020 is the primary name used for this investigational drug in clinical research. No alternative names have been reported in the context of its development by Regeneron Pharmaceuticals. The drug is being studied specifically for its potential to prevent cisplatin-induced hearing loss.